Health Care • Biotechnology: Pharmaceutical Preparations
$143.45 ▼ -0.06
(-0.04%)
MKT CAP: $7.51B • VOL: 850.5K
52W L $124 52W H $260
AXSM // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $638.5M | $385.7M | $270.6M |
| YoY Revenue Growth % | +65.5% | +42.5% | — |
| Gross Profit | $280.9M | $169.7M | $119.1M |
| Gross Margin % | 44.0% | 44.0% | 44.0% |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$166.8M | -$280.6M | -$231.8M |
| Operating Margin % | -26.1% | -72.7% | -85.7% |
| Net Income (GAAP) | -$183.2M | -$287.2M | -$239.2M |
| EBITDA (Normalized) | -$166.4M | -$280.3M | -$222.1M |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$93.4M | -$128.4M | -$145.1M |
| Capital Expenditures (CapEx) | $480.0K | $270.0K | $12.2M |
| Free Cash Flow (FCF) | -$93.9M | -$128.7M | -$157.3M |
| FCF Margin % | -14.7% | -33.4% | -58.1% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | -7.3% |
| Cash & Short-Term Equivalents | $322.9M | $315.4M | $454.6M |
| Total Debt (Short + Long Term) | $117.7M | $180.7M | $967.1M |
| Total Stockholders' Equity | $88.3M | $57.0M | $1.98B |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR AXSM.